• Anteris to offer $US200m in common stock through public offering
• Medtronic to invest up to $US90m in private placement
• Proceeds to support DurAVR® THV global pivotal trial and manufacturing expansion

Anteris Technologies Global Corp. (Nasdaq: AVR, ASX: AVR), a global structural heart company, announced that it is offering to sell $US200 million of shares of its common stock through a proposed underwritten public offering, subject to market and other conditions. The company also intends to grant the underwriters a 30-day option to purchase an additional $30 million of shares. Separately, Anteris has agreed to sell up to $US90 million of shares of common stock to Medtronic plc in a private placement, subject to a minimum purchase of 16.0% and a maximum of 19.99% of the number of shares outstanding after the public offering. The net proceeds from the offering and private placement will be used to support the next stage of growth, including ongoing recruitment and study execution of the DurAVR® Transcatheter Heart Valve (DurAVR® THV) global pivotal trial for patients with severe aortic stenosis, expansion of manufacturing capabilities, and ongoing research and development for v2vmedtech, Inc. The shares in the public offering are being offered pursuant to a shelf registration statement filed with the SEC, and the private placement shares have not been registered under the Securities Act.

Anteris intends to use the net proceeds from the $US200 million public offering, together with its existing cash and cash equivalents and the net proceeds from the $US90 million private placement to Medtronic, to support the next stage of growth and advance execution of the company's clinical strategy, including the DurAVR® Transcatheter Heart Valve global pivotal trial and expansion of manufacturing capabilities.